KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Other (2024 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Receivables - Other for 5 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Receivables - Other fell 55.0% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 55.0% year-over-year, with the annual reading at $1.8 million for FY2025, 55.0% down from the prior year.
  • Receivables - Other for Q4 2025 was $1.8 million at Supernus Pharmaceuticals, down from $6.3 million in the prior quarter.
  • The five-year high for Receivables - Other was $6.3 million in Q3 2025, with the low at $1.8 million in Q4 2025.